Tag: Castration-Resistant

Recruitment of miR-8080 by luteolin inhibits AR-V7 in castration-resistant prostate cancer

Prostate cancer is the most common noncutaneous malignancy in the United States and is responsible for many male deaths. The development of prostate carcinogenesis is initially androgen-dependent. However, the progression of castration-resistant prostate cancer (CRPC) following androgen deprivation therapy is a major clinical problem. Although enzalutamide and abiraterone have been approved for CRPC hormone therapy,

Darolutamide Slows Spread of Castration-Resistant Prostate Cancer

TUESDAY, Feb. 19, 2019 — Metastasis-free survival is significantly longer among men with nonmetastatic, castration-resistant prostate cancer treated with darolutamide versus placebo, according to a phase 3 study published online Feb. 14 in the New England Journal of Medicine to coincide with the American Society of Clinical Oncology annual Genitourinary Cancers Symposium, held from Feb.